A BCMA-specific antibody has been clinically developed as an antibody–drug conjugate and shows promising first results in patients, and BCMA-targeting CAR-T cells have shown clinical effect in a phase I study.62, 63, 64, 65 This proves that tumour antigens identified by carefully studying natural antitumour B-cell responses can be successfully employed clinically. The gene discussed is TNFRSF17; the disease is neoplasm.